Fiona A Pearce
Overview
Explore the profile of Fiona A Pearce including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
229
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lax S, Dures E, Bridgewater S, Silverthorne C, Lowndes V, Richards P, et al.
Rheumatology (Oxford)
. 2025 Mar;
PMID: 40037582
Objectives: To explore patients' perspectives on the impact of appearance changes attributed to glucocorticoid treatment. Methods: We conducted a secondary inductive thematic analysis of the 'Steroid PRO' semi-structured interviews with...
2.
Mumford L, Hogg R, Taylor A, Lanyon P, Bythell M, McPhail S, et al.
Lancet
. 2025 Jan;
405(10475):314-328.
PMID: 39863371
Background: In the UK, booster COVID-19 vaccinations have been recommended biannually to people considered immune vulnerable. We investigated, at a population level, whether the absence of detectable anti-SARS-CoV-2 spike protein...
3.
Chen A, Lax S, Grainge M, Lanyon P, Pearce F, Jeffries-Owens N, et al.
Rheumatol Adv Pract
. 2024 Nov;
8(4):rkae126.
PMID: 39524967
No abstract available.
4.
Chen A, Lax S, Grainge M, Lanyon P, Pearce F
Rheumatol Adv Pract
. 2024 Sep;
8(3):rkae086.
PMID: 39224144
Objectives: To comprehensively review systematic reviews of prevalence, incidence, and mortality of Raynaud's, Sjögren's and Scleroderma, and to identify any research gaps. Methods: An umbrella review of English language systematic...
5.
Gumber L, Jackson H, Gomez N, Hopkins G, Tucis D, Chakravorty M, et al.
Rheumatol Adv Pract
. 2024 Mar;
7(3):rkad097.
PMID: 38515961
Objective: Antibody responses to coronavirus disease 2019 (COVID-19) vaccines are reduced among immunocompromised patients but are not well quantified among people with rare disease. We conducted an observational study to...
6.
Pearce F, Lim S, Bythell M, Lanyon P, Hogg R, Taylor A, et al.
Lancet Rheumatol
. 2024 Jan;
5(8):e461-e473.
PMID: 38251578
Background: In the UK, additional COVID-19 vaccine booster doses and treatments are offered to people who are immunosuppressed to protect against severe COVID-19, but how best to choose the individuals...
7.
Rutter M, Lanyon P, Grainge M, Hubbard R, Bythell M, Stilwell P, et al.
Rheumatology (Oxford)
. 2023 Apr;
62(12):3828-3837.
PMID: 37018139
Objectives: To calculate the rates of COVID-19 infection and COVID-19-related death among people with rare autoimmune rheumatic diseases (RAIRD) during the second wave of the COVID-19 pandemic in England, and...
8.
Odingo M, Rutter M, Bowley J, Peach E, Lanyon P, Grainge M, et al.
Rheumatology (Oxford)
. 2023 Jan;
62(9):3117-3125.
PMID: 36715615
Objective: To describe the incidence of Kawasaki Disease (kDa) between 2006 and 2021 in England. Methods: We identified all cases in hospital episode statistics with an ICD-10 diagnostic code M303...
9.
Hannah J, Gordon P, Galloway J, Rutter M, Peach E, Rooney M, et al.
Rheumatol Adv Pract
. 2022 Dec;
6(3):rkac102.
PMID: 36532317
Objective: Hospital episode statistics (HES) are routinely recorded at every hospital admission within the National Health Service (NHS) in England. This study validates diagnostic ICD-10 codes within HES as a...
10.
Gumber L, Gomez N, Hopkins G, Tucis D, Bartlett L, Ayling K, et al.
Rheumatology (Oxford)
. 2022 Oct;
62(6):2294-2303.
PMID: 36250898
Objectives: Coronavirus 2019 vaccine responses in rare autoimmune rheumatic diseases (RAIRDs) remain poorly understood; in particular there is little known about whether people develop effective T cell responses. We conducted...